<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:56:18Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4383860" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4383860</identifier><datestamp>2015-04-08</datestamp><setSpec>hmg</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Hum Mol Genet</journal-id>
      <journal-id journal-id-type="iso-abbrev">Hum. Mol. Genet</journal-id>
      <journal-id journal-id-type="publisher-id">hmg</journal-id>
      <journal-id journal-id-type="hwp">hmg</journal-id>
      <journal-title-group>
        <journal-title>Human Molecular Genetics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0964-6906</issn>
      <issn pub-type="epub">1460-2083</issn>
      <publisher>
        <publisher-name>Oxford University Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4383860</article-id>
      <article-id pub-id-type="pmcid">PMC4383860</article-id>
      <article-id pub-id-type="pmc-uid">4383860</article-id>
      <article-id pub-id-type="pmid">25596185</article-id>
      <article-id pub-id-type="doi">10.1093/hmg/ddv007</article-id>
      <article-id pub-id-type="publisher-id">ddv007</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Crystal structure of human persulfide dioxygenase: structural basis of ethylmalonic encephalopathy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Pettinati</surname>
            <given-names>Ilaria</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brem</surname>
            <given-names>JÃ¼rgen</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>McDonough</surname>
            <given-names>Michael A.</given-names>
          </name>
          <xref ref-type="corresp" rid="cor1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schofield</surname>
            <given-names>Christopher J.</given-names>
          </name>
          <xref ref-type="corresp" rid="cor1">*</xref>
        </contrib>
        <aff><addr-line>Chemistry Research Laboratory</addr-line>, <institution>University of Oxford</institution>, <addr-line>12 Mansfield Road, Oxford OX1 3TA</addr-line>, <country>UK</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><label>*</label>To whom correspondence should be addressed. Tel: +<phone>44-1865275629</phone>; Fax: +<fax>44-1865285002</fax>; Email: <email>michael.mcdonough@chem.ox.ac.uk</email> (M.A.M.)/
Tel: +44-1865275625; Fax: +44-1865275674; Email: <email>christopher.schofield@chem.ox.ac.uk</email> (C.J.S.)</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>01</day>
        <month>5</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>16</day>
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>16</day>
        <month>1</month>
        <year>2015</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. -->
      <volume>24</volume>
      <issue>9</issue>
      <fpage>2458</fpage>
      <lpage>2469</lpage>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>12</month>
          <year>2014</year>
        </date>
        <date date-type="rev-recd">
          <day>6</day>
          <month>1</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>1</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© The Author 2015. Published by Oxford University Press.</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="ddv007.pdf"/>
      <abstract>
        <p>The ethylmalonic encephalopathy protein 1 (ETHE1) catalyses the oxygen-dependent oxidation of glutathione persulfide (GSSH) to give persulfite and glutathione. Mutations to the <italic>hETHE1</italic> gene compromise sulfide metabolism leading to the genetic disease ethylmalonic encephalopathy. hETHE1 is a mono-iron binding member of the metallo-Î²-lactamase (MBL) fold superfamily. We report crystallographic analysis of hETHE1 in complex with iron to 2.6 Ã resolution. hETHE1 contains an Î±Î²Î²Î± MBL-fold, which supports metal-binding by the side chains of an aspartate and two histidine residues; three water molecules complete octahedral coordination of the iron. The iron binding hETHE1 enzyme is related to the âclassicalâ di-zinc binding MBL hydrolases involved in antibiotic resistance, but has distinctive features. The histidine and aspartate residues involved in iron-binding in ETHE1, occupy similar positions to those observed across both the zinc 1 and zinc 2 binding sites in classical MBLs. The active site of hETHE1 is very similar to an ETHE1-like enzyme from <italic>Arabidopsis thaliana</italic> (60% sequence identity). A channel leading to the active site is sufficiently large to accommodate a GSSH substrate. Some of the observed hETHE1 clinical mutations cluster in the active site region. The structure will serve as a basis for detailed functional and mechanistic studies on ETHE1 and will be useful in the development of selective MBL inhibitors.</p>
      </abstract>
    </article-meta>
  </front>
  <body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Ethylmalonic encephalopathy (EE; OMIM: 602473) is an inborn autosomal-recessive disorder that has severe gastrointestinal and neurological effects in infants (<xref rid="DDV007C1" ref-type="bibr">1</xref>â<xref rid="DDV007C3" ref-type="bibr">3</xref>). EE is caused by mutations to the gene (HGNC: 23287) encoding for the ethylmalonic encephalopathy protein 1 (ETHE1, also known as sulphur dioxygenase, SDO) (<xref rid="DDV007C4" ref-type="bibr">4</xref>â<xref rid="DDV007C6" ref-type="bibr">6</xref>) and correlates with increased cellular levels of hydrogen sulfide. Although hydrogen sulfide is highly toxic above low threshold levels, it is also proposed as a gaseous redox signalling molecule. Thus, abnormally increased hydrogen sulfide levels have the potential to result in highly pleiotropic and toxic effects consistent with the lethal phenotype observed in infants with EE (<xref rid="DDV007C7" ref-type="bibr">7</xref>). ETHE1 is proposed to play a role in other diseases, including acute myocardial infarction and cardiovascular disorders (<xref rid="DDV007C8" ref-type="bibr">8</xref>,<xref rid="DDV007C9" ref-type="bibr">9</xref>). A deficiency of hydrogen sulfide is proposed to be of pathophysiological relevance, arising perhaps as a consequence of cross-talk with nitric oxide or other reactive oxygen species involved in signalling (<xref rid="DDV007C10" ref-type="bibr">10</xref>). ETHE1 is reported to be localized to mitochondria where its activity is linked to electron transfer chain energy generation and is of central importance in hydrogen sulfide metabolism (<xref rid="DDV007C11" ref-type="bibr">11</xref>). ETHE1 is a non-heme iron-dependent oxygenase that catalyses the biochemically interesting oxidation of glutathione persulfide (GSSH) to give glutathione and persulfite (<xref rid="DDV007C11" ref-type="bibr">11</xref>) [Eq. (1)].<disp-formula><mml:math xmlns:mml="https://jats.nlm.nih.gov/ns/archiving/1.0/" id="DmEquation1"><mml:mtext>GSSH +Â </mml:mtext><mml:mrow><mml:msub><mml:mtext>O</mml:mtext><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:msub><mml:mtext>H</mml:mtext><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mtext>O</mml:mtext><mml:mspace width="thinmathspace"/><mml:mrow><mml:mrow><mml:mrow><mml:mover><mml:mo stretchy="false">â</mml:mo><mml:mrow><mml:mtext>hETHE1</mml:mtext></mml:mrow></mml:mover></mml:mrow></mml:mrow></mml:mrow><mml:mspace width="thinmathspace"/><mml:msubsup><mml:mtext>GSH + SO</mml:mtext><mml:mn>3</mml:mn><mml:mrow><mml:mn>2</mml:mn><mml:mo>â</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:msup><mml:mtext>H</mml:mtext><mml:mo>+</mml:mo></mml:msup></mml:mrow><mml:mo>.</mml:mo></mml:math></disp-formula>
Sequence analyses predict that hETHE1 is a member of the widely distributed metallo-Î²-lactamase (MBL)-fold family (<xref rid="DDV007C5" ref-type="bibr">5</xref>). MBL-fold proteins were first isolated from prokaryotes showing Î²-lactam antibiotic resistance (<xref rid="DDV007C12" ref-type="bibr">12</xref>); these classical MBLs are di-, or less commonly mono-, zinc-ion-dependent hydrolases; they act on almost all known Î²-lactam antibiotics, including carbapenems and are an increasing clinical concern (<xref rid="DDV007C13" ref-type="bibr">13</xref>â<xref rid="DDV007C15" ref-type="bibr">15</xref>). The first description of an MBL crystal structure (i.e. that of the <italic>Bacillus cereus</italic> MBL) revealed a new protein fold containing an alpha-beta-beta-alpha core fold and distinctive active site architecture (<xref rid="DDV007C12" ref-type="bibr">12</xref>). Subsequent studies revealed three classes of MBLs: B1, B2 and B3. The MBL enzymes are characterized by the presence of five highly, but not universally, conserved active site elements (motifs) distributed across the MBL-fold (<xref rid="DDV007C16" ref-type="bibr">16</xref>): motif 1, D84 (which is not directly involved in zinc binding); motif 2, H116-X-H118-X-D120; H121 is present in class B3 MBLs and some human MBL-fold enzymes (hMBLs); motif 3, H196; motif 4, C221; and motif 5, H263 (<xref rid="DDV007C12" ref-type="bibr">12</xref>,<xref rid="DDV007C16" ref-type="bibr">16</xref>,<xref rid="DDV007C17" ref-type="bibr">17</xref>). In classical di-zinc B1 MBLs these residues normally bind two neighbouring metal ions in the active site: zinc 1 is coordinated by the side chains of H116, H118 and H196. Zinc 2 is coordinated by the side chains of D120, C221 and H263 (Fig. <xref ref-type="fig" rid="DDV007F1">1</xref>). Subsequent work has revealed that the MBL-fold is extremely widespread and found in enzymes with a range of biological functions (<xref rid="DDV007C18" ref-type="bibr">18</xref>). In humans, MBL-fold enzymes have roles in detoxification [i.e. ETHE1 and hydroxyacylglutathione hydrolase (HAGH), also called glyoxalase II] (<xref rid="DDV007C11" ref-type="bibr">11</xref>,<xref rid="DDV007C19" ref-type="bibr">19</xref>), DNA repair (DNA cross-link repair 1A-B-C) (<xref rid="DDV007C20" ref-type="bibr">20</xref>) and RNA processing and maturation (cleavage and polyadenylation specific factor family members) (<xref rid="DDV007C21" ref-type="bibr">21</xref>,<xref rid="DDV007C22" ref-type="bibr">22</xref>). The diversity of biological roles observed for MBL-fold enzymes is apparently reflected by variations in their active site metallo-chemistry. At present, the available evidence suggests that the majority of MBL-fold enzymes employ one or two zinc ions for catalysis in hydrolytic reactions. However, many MBL-fold hydrolases, including the classical MBLs, are able to employ other metal ions [i.e. Mg(II), Ca(II), Co(II)] and/or mixtures of metals for catalysis (<xref rid="DDV007C23" ref-type="bibr">23</xref>,<xref rid="DDV007C24" ref-type="bibr">24</xref>). In this regard, ETHE1 is of particular interest because it employs a single non-heme iron ion to catalyse a reaction that is reminiscent of those catalysed by structurally unrelated non-heme iron-dependent oxygenases; in particular isopenicillin N synthase (IPNS), which is an unusual member of the iron and 2-oxoglutarate (2OG)-dependent oxygenase superfamily (<xref rid="DDV007C25" ref-type="bibr">25</xref>â<xref rid="DDV007C27" ref-type="bibr">27</xref>), and cysteine dioxygenase (<xref rid="DDV007C28" ref-type="bibr">28</xref>,<xref rid="DDV007C29" ref-type="bibr">29</xref>). These enzymes have related metal-coordination chemistry to the MBL-fold enzyme superfamily (<xref rid="DDV007C30" ref-type="bibr">30</xref>); here we report crystallographic studies on human ETHE1. The structural work provides insights into the effects of clinically observed <italic>ETHE1</italic> mutations (<xref rid="DDV007C4" ref-type="bibr">4</xref>â<xref rid="DDV007C6" ref-type="bibr">6</xref>), and, by comparison with the structure of an <italic>Arabidopsis thaliana</italic> ETHE1-like enzyme (<xref rid="DDV007C31" ref-type="bibr">31</xref>), shows active site features that distinguish the ETHE1s from other MBL-fold containing enzymes.
<fig id="DDV007F1" position="float"><label>Figure 1.</label><caption><p>Comparison of hETHE1 active site with those of the Class B1, B2 and B3 prokaryotic MBLs. (<bold>A</bold>) Wall-eyed stereoviews of superimposed active site residues from the Class B1 MBL BcII from <italic>Bacillus cereus</italic> (PDB ID: 1BVT) (orange), the Class B2 MBL CphA from <italic>Aeromonas hydrophila</italic> (PDB ID: 3F9O) (pink) and the Class B3 MBL FEZ-1 from <italic>Legionella gormanii</italic> (PDB ID: 1K07) (blue). The standard BBL numbering system for MBLs is used (<xref rid="DDV007C17" ref-type="bibr">17</xref>). Residues present in all the three active sites are numbered in black, zinc ions are in light-orange (BcII), light-pink (CphA) and light-blue (FEZ-1). Note that the zinc-ligating residue His121 is only present in the Class B3 FEZ-1, whereas Cys221 is absent in the FEZ-1 B3 MBL compared with the Class B1 and B2 MBLs. The FEZ-1 active site residue composition is most similar to that of the hMBLs, despite the latter apparently displaying closer similarity with the Class B1 MBLs from an overall structural perspective (see Fig. <xref ref-type="fig" rid="DDV007F6">6</xref>). (<bold>B</bold>) Wall-eyed stereoview of the hETHE1 active site residues. The hETHE1 residue numbering is in blue and based on the enzyme sequence; BBL numbering is shown below in black. Note that in superimposition of hETHE1 with BcII (Fig. <xref ref-type="fig" rid="DDV007F6">6</xref>C), His79<sub>ETHE1</sub> (His116<sub>BBL</sub>) does not correlate with His116<sub>BBL</sub> of BcII, but with His118<sub>BBL</sub> showing a different organization of conserved residues in their active sites. Note that the side chains of His84<sub>ETHE1</sub> (His121<sub>BBL</sub>) and FEZ-1 His121<sub>BBL</sub> are observed in different orientations in their respective active sites, probably because His121<sub>BBL</sub> of FEZ-1 is involved in an additional metal binding (zinc 2 site), which is not observed in hETHE1.</p></caption><graphic xlink:href="ddv00701"/></fig></p></sec><sec sec-type="results" id="s2"><title>Results</title><sec id="s2a"><title>Overall fold of hETHE1</title><p>Recombinant hETHE1 lacking its 20 residue N-terminal mitochondrial targeting sequence was produced in <italic>Escherichia coli</italic> and highly purified (â¥95%) as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis (<ext-link ext-link-type="uri" xlink:href="http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddv007/-/DC1">Supplementary Material, Fig. S1</ext-link>). hETHE1 was crystallized using the sitting drop vapour diffusion method. The final model (orthorhombic space group <italic>P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>) has two chains representing the dimer in the asymmetric unit.</p><p>The hETHE1 structure reveals an Î±Î²Î²Î± MBL-type fold with two central mixed Î²-sheets, each containing six strands, surrounded on both sides by helices (Fig. <xref ref-type="fig" rid="DDV007F2">2</xref>A and <ext-link ext-link-type="uri" xlink:href="http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddv007/-/DC1">Supplementary Material, Fig. S2</ext-link>). In Î²-sheet I, Î²-strands 1â3 are aligned anti-parallel, with Î²-strands 3â6 being parallel. In Î²-sheet II, Î²-strands 7, 8, 9 and 10 are anti-parallel; Î²-strands 10 and 13 are parallel and Î²-strands 13 and 14 are anti-parallel (<ext-link ext-link-type="uri" xlink:href="http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddv007/-/DC1">Supplementary Material, Fig. S2A</ext-link>). Secondary structural elements include: 2 Î²-sheets, 2 Î²Î±Î²Î± units, 8 Î²-hairpins, 6 Î²-bulges, 14 Î²-strands, 6 helices, 2 helixâhelix interactions and 26 Î²-turns. Superimposition of the hETHE1 and <italic>A. thaliana</italic> ETHE1-like (PDB ID: 2GCU) structures reveals high overall fold similarity [root-mean-square deviation (RMSD) 1.43 Ã over 230 CÎ± atoms] between the two proteins (Fig. <xref ref-type="fig" rid="DDV007F2">2</xref>B). Structure-based topology diagrams show conserved structural organization with the exception of the addition of the Î²11âÎ²12 hairpin in the region linking Î²10 and Î²13 of the core fold of hETHE1 compared with the <italic>A. thaliana</italic> ETHE1 (<ext-link ext-link-type="uri" xlink:href="http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddv007/-/DC1">Supplementary Material, Figs S2A and B</ext-link>). Topology comparisons of hETHE1 with human glyoxalase II (HAGH) and a âclassicalâ metallo-Î²-lactamase II (BcII) from <italic>B. cereus</italic> (<ext-link ext-link-type="uri" xlink:href="http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddv007/-/DC1">Supplementary Material, Fig. S2C and D</ext-link>) reveal much more substantial differences in the organization of secondary structure elements. hETHE1 has been assigned as a member of the glyoxalase II family on the basis of sequence alignments (<xref rid="DDV007C31" ref-type="bibr">31</xref>); however, consistent with the differences in their overall folds (<xref rid="DDV007C19" ref-type="bibr">19</xref>), hETHE1 does not display glyoxalase II activity, when assayed using the most common glyoxalase II substrate, <italic>S</italic>-(D)-lactoylglutathione, under standard conditions (<xref rid="DDV007C11" ref-type="bibr">11</xref>). Enzyme-dependent oxygen consumption activity in the presence of GSSH was observed using the oxygen consumption assay as previously reported (<xref rid="DDV007C11" ref-type="bibr">11</xref>) (Fig. <xref ref-type="fig" rid="DDV007F3">3</xref>A). Moreover, ETHE1 does not display Î²-lactamase activity either using a chromogenic cephalosporin (nitrocefin), a penicillin (penicillin G) or a carbapenem (meropenem) as substrates under our standard Î²-lactamase assay conditions (<xref rid="DDV007C32" ref-type="bibr">32</xref>).
<fig id="DDV007F2" position="float"><label>Figure 2.</label><caption><p>Views from the hETHE1 crystal structure. (<bold>A</bold>) Wall-eyed stereoview of hETHE1 showing secondary structure elements and the mono iron containing active site. Helices are blue, Î²-strands yellow and the iron is an orange sphere. (<bold>B</bold>) Wall-eyed stereoview of the superposition of hETHE1 (blue) and the <italic>A. thaliana</italic> ETHE1-like enzyme (red) (RMSD 1.43 Ã over 230 CÎ± atoms). The structures reveal very similar overall folds except for small differences in the Î²2âÎ²3 and Î²9âÎ²10 loops. (<bold>C</bold>) The crystallographically observed hETHE1 dimer. Active sites for both chains exist on the same face of the dimer. Chains A and B are in cyan and green, respectively.</p></caption><graphic xlink:href="ddv00702"/></fig>
<fig id="DDV007F3" position="float"><label>Figure 3.</label><caption><p>hETHE1 activity assay and oligomerization state. (<bold>A</bold>) Oxygen consumption activity assay. hETHE1 activity was measured as percentage of oxygen consumed in the presence of GSSH. Each sample was performed in triplicate. (<bold>B</bold>) Non-denaturing electrospray soft-ionization mass spectrometry deconvoluted spectrum of purified hETHE1 protein indicates that hETHE1 is primarily dimeric. Peak A (26 170 Da) represents monomer; peak B (52370 Da) the dimer. In both monomeric and dimeric states one iron ion (+56 Da) is bound to each protomer while only in the dimer a +30 Da was observed possibly due to the oxidation state of Cys247 (see the main text and <ext-link ext-link-type="uri" xlink:href="http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddv007/-/DC1">Supplementary Material, Fig. S5</ext-link>) (conditions: 15 Âµ<sc>m</sc> of hETHE1 in 15 m<sc>m</sc> ammonium acetate buffer (pH 7.5); cone voltage for the acquisition of the spectra was 80 V). (<bold>C</bold>) MALS analysis of hETHE1 protein after purification. Peak A (â¼51 560 Da) represents monomer; peak B (â¼99 190 Da) the tetramer. MALS experiments were carried out by the Biophysical Services of the Biochemistry Department of Oxford University. (<bold>D</bold>) The molecular mass of hETHE1 in solution was estimated using a Sephadex G250 gel filtration column calibrated with protein standards [beta-amylase (223 kDa), albumin (66 kDa), carbonic anhydrase (29 kDa) and cytochrome C (12 kDa)].</p></caption><graphic xlink:href="ddv00703"/></fig></p><p>As reported for the <italic>A. thaliana</italic> protein (<xref rid="DDV007C33" ref-type="bibr">33</xref>), hETHE1 is predominantly a dimer in solution. Non-denaturing mass spectrometric and multi-angle laser light scattering (MALS) analyses indicate that hETHE1 is predominantly dimeric with some monomer also being observed (dimer to monomer ratio â¼10:1); quantitative gel filtration analysis indicated a mass for hETHE1 intermediate between monomeric (26 116 Da) and dimeric (52 232 Da) forms in solution (Fig. <xref ref-type="fig" rid="DDV007F3">3</xref>BâD). The crystal packing of the human ETHE1 is similar to that reported for the <italic>A. thaliana</italic> ETHE1-like structure (<xref rid="DDV007C31" ref-type="bibr">31</xref>), with both hETHE1 and <italic>A. thaliana</italic> ETHE1-like crystallizing as dimers. Interactions at the crystallographically observed hETHE1 dimer interface were analysed by PISA (<xref rid="DDV007C34" ref-type="bibr">34</xref>) to investigate their potential for functional relevance. The total buried surface area at the interface is 1950 Ã<sup>2</sup> and the calculated free energy of binding (Î<italic>G</italic>) for the dimer is about â37 kcal/mol. The calculated complex formation significance score (CSS) value of 0.351 output from PISA is consistent with the observed dimer formation in solution (Fig. <xref ref-type="fig" rid="DDV007F2">2</xref>C). Notably, conserved interactions are present at the dimer interface of both human and <italic>A. thaliana</italic> ETHE1-like even though the proteins were crystallized under very different conditions.</p></sec><sec id="s2b"><title>hETHE1 active site</title><p>The active site of each hETHE1 protomer in the asymmetric unit contains a single iron ion (Fig. <xref ref-type="fig" rid="DDV007F2">2</xref>C). Analysis of the enzyme surface reveals a channel, comprised of residues 163â166 and 226â232, leading to the active site that is sufficient to accommodate a substrate molecule of GSSH (Fig. <xref ref-type="fig" rid="DDV007F4">4</xref>A and B); this channel is apparently conserved in the <italic>A. thaliana</italic> ETHE1. Residues making up the channel may also act in the stabilization of intermediates and/or product release. Manual docking of GSSH into the hETHE1 active site (Fig. <xref ref-type="fig" rid="DDV007F5">5</xref>) is consistent with the proposed mechanism of catalysis involving an Fe-SSG intermediate (<ext-link ext-link-type="uri" xlink:href="http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddv007/-/DC1">Supplementary Material, Fig. S3</ext-link>).
<fig id="DDV007F4" position="float"><label>Figure 4.</label><caption><p>hETHE1 surface analysis. (<bold>A</bold>) Surface representation of the crystallographically observed hETHE1 dimer (chain A cyan, chain B green). Metal binding residues shown as sticks, iron ion shown as orange sphere. (<bold>B</bold>) Surface representation of the active site groove showing the side chain of Tyr197 directed towards the metal (6.8 Ã). (<bold>C</bold>) The side chain of Cys247 was refined as a sulfinic acid (CSD247) (i.e. RSO<sub>2</sub>H) as observed in the experimental electron density (3.0 <italic>Ï</italic> mFo-DFc OMIT, omitting oxygen atoms; green mesh). The two serine residues (Ser 88 and Ser 100) are only weakly conserved whilst Cys247 is conserved in most predicted ETHE enzymes as shown in Figure <xref ref-type="fig" rid="DDV007F7">7</xref>.</p></caption><graphic xlink:href="ddv00704"/></fig>
<fig id="DDV007F5" position="float"><label>Figure 5.</label><caption><p>Docking of GSSH in hETHE1 active site. GSSH was manually docked into the active site groove using the shape of the groove and an electrostatic surface potential map as a guide. The GSSH thiol was restrained near the metal ion and the glycyl carboxylate of GSSH was orientated towards the positively charged end of the pocket so that the primary amine on the opposite end of the chain faced the negatively charged surface. The ligand is surrounded by the Î±5âÎ±6 loop on one side of the groove and by Tyr197 on the other side. All manual docking was performed using Pymol. (<bold>A</bold>) Ribbons representation of GSSH manually docked into the ETHE1 active site. (<bold>B</bold>) Wall-eyed stereoview of the hETHE1 active site and surrounding residues possibly participating in substrate binding and/or stabilization. (<bold>C</bold>) Enlarged view of GSSH docked in the hETHE1 active site. (<bold>D</bold>) Surface representation of GSSH docked in hETHE1 active site groove. Note the possible substrate interaction with Tyr197 and Arg214.</p></caption><graphic xlink:href="ddv00705"/></fig></p><p>Interestingly, three of five characteristic MBL family metal-binding motif residues (<xref rid="DDV007C35" ref-type="bibr">35</xref>), His79, His135 and Asp154 (corresponding to His118, His196, and Cys221, BBL numbering system), act as iron coordinating residues in hETHE1 (Fig. <xref ref-type="fig" rid="DDV007F6">6</xref>A). Three water molecules complete the metal coordination. Residues His81<sub>ETHE1</sub> (His118<sub>BBL</sub>), Asp83<sub>ETHE1</sub> (Asp120<sub>BBL</sub>) and His195<sub>ETHE1</sub> (His263<sub>BBL</sub>) are present in the hETHE1 active site, but are not involved in metal coordination as observed in the current structural data. The position of Asp83<sub>ETHE1</sub> and His195<sub>ETHE1</sub> somewhat resembles the zinc 2 organization of the classical MBLs (<xref rid="DDV007C12" ref-type="bibr">12</xref>) (Fig. <xref ref-type="fig" rid="DDV007F6">6</xref>B). However, the side chain carboxylate of Asp52<sub>ETHE1</sub> (Asp84<sub>BBL</sub>) is â¼6 Ã from the iron ion.
<fig id="DDV007F6" position="float"><label>Figure 6.</label><caption><p>hETHE1 active site and comparison of the hETHE1 crystal structure with other MBL-fold enzymes. (<bold>A</bold>) Wall-eyed stereoview of the iron binding and active site residues of hETHE1 with representative electron density (3.0 <italic>Ï</italic> mFo-DFc OMIT; green mesh) for side chains of His79 (NÏµ2 to Fe: 2.3 Ã), His135 (NÏµ2 to Fe: 2.22 Ã), Asp 154 (OÎ´2 to Fe: 2.05 Ã) and the three water molecules (red spheres) which coordinate (black dashed lines) to the iron (orange sphere). (<bold>B</bold>) Wall-eyed stereoview of superimposed active site residues from hETHE1 (cyan) and BcII from <italic>Bacillus cereus</italic> (PDB ID: 1BVT) (orange). The zinc and iron ions are in grey and dark red, respectively. The zinc ions in the Zn<sub>1</sub> and Zn<sub>2</sub> sites are labelled (<xref rid="DDV007C17" ref-type="bibr">17</xref>). There is relatively strong conservation in iron-binding residues by ETHE1 and at the Zn<sub>1</sub> site of glyoxalase II; although the Zn<sub>2</sub> binding site residues are conserved in hETHE1, they do not bind the iron ion. (<bold>C</bold>) Wall-eyed stereoview of the superimposed active site residues from hETHE1 (cyan) and human glyoxalase II (PDB ID: 1QH3/5) (green). <italic>Note</italic>. There are more differences between hETHE1 and BcII than between hETHE1 and glyoxalase II.</p></caption><graphic xlink:href="ddv00706"/></fig></p><p>Comparison of the hETHE1 and <italic>A. thaliana</italic> ETHE1 structures reveals similar iron binding with near identical orientations and metal distances between conserved residues (Fig. <xref ref-type="fig" rid="DDV007F2">2</xref>B). Comparison of the active sites of hETHE1 and human glyoxalase II (HAGH) (which binds two zinc ions) shows that they display partial similarity in zinc 1 coordinating residues: HAGH uses His54<sub>GII</sub>, His110<sub>GII</sub> and Asp134<sub>GII</sub> to coordinate zinc and hETHE1 uses His79<sub>ETHE1</sub>, His135<sub>ETHE1</sub> and Asp154<sub>ETHE1</sub> to coordinate iron. The major difference between the hETHE1 and hHAGH active sites is the number of bound metals, with zinc 2 of hHAGH interacting with conserved MBL motif residues, Asp58<sub>GII</sub>, His59<sub>GII</sub> and His173<sub>GII</sub>, which correspond to Asp83<sub>ETHE1</sub>, His84<sub>ETHE1</sub> and His195<sub>ETHE1</sub> of ETHE1 (Asp120<sub>BBL</sub>, class B3 His121<sub>BBL</sub> and His263<sub>BBL</sub>). The similarity of residues used for zinc 2 binding in hHAGH compared with those in the hETHE1 active site may explain why hETHE1 has been previously identified as a close relative of the glyoxalase II family (<xref rid="DDV007C19" ref-type="bibr">19</xref>) (Fig. <xref ref-type="fig" rid="DDV007F6">6</xref>C).</p><p>Superimposition of the hETHE1 structure with that of the prototypical bacterial MBL class B1 enzyme, BcII, also reveals a similar active site. The BcII MBL has two zinc ions in its active site with zinc 1 coordinated by three histidines (His116<sub>BBL</sub>, His118<sub>BBL</sub> and His196<sub>BBL</sub>), and zinc 2 coordinated by Asp120<sub>BBL</sub>, Cys221<sub>BBL</sub> and His263<sub>BBL</sub> (Fig. <xref ref-type="fig" rid="DDV007F6">6</xref>B). Sequence comparison reveals that Cys221<sub>BBL</sub> is apparently not present in the metal-binding motifs of hMBLs (Fig. <xref ref-type="fig" rid="DDV007F7">7</xref>).
<fig id="DDV007F7" position="float"><label>Figure 7.</label><caption><p>Multiple sequence alignment of ETHE1 from different organisms. COBALT BLAST (<xref rid="DDV007C36" ref-type="bibr">36</xref>) was used to align sequences identified in a BLAST search (<xref rid="DDV007C37" ref-type="bibr">37</xref>). The hETHE1 sequence was used as the query and the secondary structure elements are derived from the human ETHE1 structure (PDB ID 4CHL). Secondary structure elements were inserted using the ESPRIT 3 tool (<uri xlink:type="simple" xlink:href="http://espript.ibcp.fr">http://espript.ibcp.fr</uri>) (<xref rid="DDV007C38" ref-type="bibr">38</xref>). Î²-Sheets are shown as yellow arrows, and Î±-helices as blue sinusoidal waves. Residues are coloured based on conservation: dark blue represents the highest conservation grade, light blue the second highest, grey the third highest and no colour the least conserved. The MBL-fold proteins glyoxalase II from <italic>Homo sapiens</italic> and <italic>Arabidopsis thaliana</italic> were added to the multiple sequence alignment. The three iron-binding residues (His79, His135 and Asp154) are highlighted in green; Tyr197 and Cys247 are in pink. Red asterisk (*) indicates a site 2 Zn binding residue of Glyoxalase II (note that Asp134 binds both zinc ions in the Glyoxalase II active site).</p></caption><graphic xlink:href="ddv00707"/></fig></p><p>Two residues of interest in the hETHE1 structure are Cys247 and Tyr197. hETHE1 appears to be modified as shown by non-denaturing mass spectrometry experiments by the addition of two oxygen atoms and Cys247 was refined as a cysteinyl sulfinic acid (RSO<sub>2</sub>H) (Protein Data Bank acronym: CSD) (Figs <xref ref-type="fig" rid="DDV007F3">3</xref>B and <xref ref-type="fig" rid="DDV007F4">4</xref>C). We considered that the observed oxidation state of Cys247 may be an artefact derived from protein preparation. Interestingly, however, crystallographic analysis has revealed that the equivalent cysteine (Cys246) in the <italic>A. thaliana</italic> ETHE1-like structure is also observed to be doubly oxidized supporting the potential for a function for this residue. The possibility of autocatalytic oxidation of Cys247 in ETHE1 is well precedented in metallo-enzymes including nitrile hydratase, where two of three active site clustered cysteine residues are post-translationally oxidized to sulfinic acid and sulfenic acid, respectively, modifications that are essential for catalytic activity (<xref rid="DDV007C39" ref-type="bibr">39</xref>,<xref rid="DDV007C40" ref-type="bibr">40</xref>). The oxidation of Cys247 is also notable because the hETHE1 reaction involves oxidation of a thiol to give persulfite [Eq. (1)]. It is thus possible that oxidation of Cys247 is either of catalytic relevance or represents a non-productive/damaging protein oxidation, as is well precedented in other oxygenases and metallo-proteins (<xref rid="DDV007C41" ref-type="bibr">41</xref>) including haemoglobin (<xref rid="DDV007C42" ref-type="bibr">42</xref>). Tyr197 is highly conserved in ETHE1 across different organisms including <italic>A. thaliana</italic> (<xref rid="DDV007C31" ref-type="bibr">31</xref>), but it is not apparently conserved among prokaryotic MBLs or hMBL-fold enzymes with the exception of HAGH (<xref rid="DDV007C19" ref-type="bibr">19</xref>) and paroxysmal nonkinesigenic dyskinesia protein (PNKD) (<xref rid="DDV007C43" ref-type="bibr">43</xref>). Tyr197 is positioned in the active site with its side chain hydroxyl directed towards the active site metal (Figs <xref ref-type="fig" rid="DDV007F4">4</xref>B and <xref ref-type="fig" rid="DDV007F5">5</xref>). Given the proposed role of electron transfer in the catalytic mechanism of ETHE1 as shown in <ext-link ext-link-type="uri" xlink:href="http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddv007/-/DC1">Supplementary Material, Figure S3</ext-link>, it is possible that the phenolic group of Tyr197 has an active role in catalysis, as proposed for some other non-heme iron-dependent oxygenases, e.g. carbapenem synthase (<xref rid="DDV007C44" ref-type="bibr">44</xref>,<xref rid="DDV007C45" ref-type="bibr">45</xref>).</p></sec><sec id="s2c"><title>Mapping clinically observed EE mutations on the hETHE1 structure</title><p>Mutations have been identified in the <italic>h</italic>ETHE1 gene of individuals with EE (Table <xref ref-type="table" rid="DDV007TB1">1</xref>) (<xref rid="DDV007C6" ref-type="bibr">6</xref>). We used the hETHE1 structure to map 13 missense-mutations resulting in EE disease (Fig. <xref ref-type="fig" rid="DDV007F8">8</xref>; substituted residues in pink or magenta). Interestingly, the Asp196 substitution is positioned immediately before Tyr197 and is reported to lead to decreased substrate affinity (<xref rid="DDV007C6" ref-type="bibr">6</xref>,<xref rid="DDV007C11" ref-type="bibr">11</xref>), supporting a proposed role for Tyr197 in substrate binding/catalysis. Moreover, with the exception of Gln12, all EE disease correlating substitutions occur at positions of conserved (Glu63, Cys161), or highly conserved (Tyr38, Leu55, Thr136, Thr152, Arg163, Thr164, Asp165, Leu185 and Asp196), residues, reflecting their likely importance in protein function and maintenance of overall structure (Fig. <xref ref-type="fig" rid="DDV007F8">8</xref>). Interestingly, substitutions resulting in EE disease have been observed at residues lining the proposed substrate binding channel, Arg163, Tyr164 and Asp165 (<xref rid="DDV007C5" ref-type="bibr">5</xref>,<xref rid="DDV007C6" ref-type="bibr">6</xref>). The structural information supports the recent discovery that mutations occurring at Arg163 are able to alter hETHE1 stability and the active site metal chemistry (<xref rid="DDV007C49" ref-type="bibr">49</xref>). Some of the substitutions involve residues preceding or following the active site iron-binding residues, in particular, variants of Thr136, Thr152 and Asp196 (i.e. adjacent or close to the metal coordinating residues, His135, Asp154 and His195, respectively). Substitutions at these likely crucial positions in the structure could lead to instability and/or conformational changes to the active site (<xref rid="DDV007C11" ref-type="bibr">11</xref>) and may help to explain how a single point mutation results in a catalytically compromised hETHE1.
<table-wrap id="DDV007TB1" position="float"><label>Table 1.</label><caption><p>Clinically observed mutations in hETHE1 that correlate with EE</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Residue number</th><th align="center" colspan="2" rowspan="1">Substitution<hr/></th><th align="left" rowspan="2" colspan="1">Reference/reported substitution effects</th></tr><tr><th align="left" rowspan="1" colspan="1">From</th><th align="left" rowspan="1" colspan="1">To</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">Q</td><td rowspan="1" colspan="1">X</td><td rowspan="1" colspan="1">(<xref rid="DDV007C4" ref-type="bibr">4</xref>)</td></tr><tr><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">Y</td><td rowspan="1" colspan="1">C</td><td rowspan="1" colspan="1">Reduced protein stability (<xref rid="DDV007C5" ref-type="bibr">5</xref>)</td></tr><tr><td rowspan="1" colspan="1">55</td><td rowspan="1" colspan="1">P</td><td rowspan="1" colspan="1">L</td><td rowspan="1" colspan="1">Reduced protein production (<xref rid="DDV007C6" ref-type="bibr">6</xref>)</td></tr><tr><td rowspan="1" colspan="1">63</td><td rowspan="1" colspan="1">Q</td><td rowspan="1" colspan="1">X</td><td rowspan="1" colspan="1">(<xref rid="DDV007C4" ref-type="bibr">4</xref>)</td></tr><tr><td rowspan="1" colspan="1">136</td><td rowspan="1" colspan="1">T</td><td rowspan="1" colspan="1">A/G</td><td rowspan="1" colspan="1">(<xref rid="DDV007C5" ref-type="bibr">5</xref>,<xref rid="DDV007C6" ref-type="bibr">6</xref>)</td></tr><tr><td rowspan="1" colspan="1">152</td><td rowspan="1" colspan="1">T</td><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">Reduced protein stability, iron content, enzyme activity (<xref rid="DDV007C6" ref-type="bibr">6</xref>,<xref rid="DDV007C11" ref-type="bibr">11</xref>)</td></tr><tr><td rowspan="1" colspan="1">161</td><td rowspan="1" colspan="1">C</td><td rowspan="1" colspan="1">Y</td><td rowspan="1" colspan="1">(<xref rid="DDV007C4" ref-type="bibr">4</xref>)</td></tr><tr><td rowspan="1" colspan="1">163</td><td rowspan="1" colspan="1">R</td><td rowspan="1" colspan="1">Q/W/G</td><td rowspan="1" colspan="1">Reduced protein stability, reduction potential of iron, enzyme activity (<xref rid="DDV007C46" ref-type="bibr">46</xref>)</td></tr><tr><td rowspan="1" colspan="1">164</td><td rowspan="1" colspan="1">T</td><td rowspan="1" colspan="1">K</td><td rowspan="1" colspan="1">Reduced protein stability (<xref rid="DDV007C5" ref-type="bibr">5</xref>,<xref rid="DDV007C6" ref-type="bibr">6</xref>)</td></tr><tr><td rowspan="1" colspan="1">165</td><td rowspan="1" colspan="1">D</td><td rowspan="1" colspan="1">G</td><td rowspan="1" colspan="1">(<xref rid="DDV007C5" ref-type="bibr">5</xref>)</td></tr><tr><td rowspan="1" colspan="1">185</td><td rowspan="1" colspan="1">L</td><td rowspan="1" colspan="1">R</td><td rowspan="1" colspan="1">(<xref rid="DDV007C6" ref-type="bibr">6</xref>)</td></tr><tr><td rowspan="1" colspan="1">196</td><td rowspan="1" colspan="1">D</td><td rowspan="1" colspan="1">N</td><td rowspan="1" colspan="1">Reduced protein stability/substrate affinity (<xref rid="DDV007C6" ref-type="bibr">6</xref>,<xref rid="DDV007C11" ref-type="bibr">11</xref>)</td></tr></tbody></table><table-wrap-foot><fn id="TN1"><p>Reported clinical mutations for hETHE1 that result in EE (<xref rid="DDV007C4" ref-type="bibr">4</xref>â<xref rid="DDV007C6" ref-type="bibr">6</xref>,<xref rid="DDV007C11" ref-type="bibr">11</xref>). Where reported, the effects of the mutation at the protein level are given. Substitutions indicated with X represent nonsense mutations that encode for truncated versions of hETHE1. Protein stability was measured based on the levels of ETHE1-protein-specific cross-reacting material (CRM) present in fibroblasts as detected by western blotting (<xref rid="DDV007C5" ref-type="bibr">5</xref>).</p></fn></table-wrap-foot></table-wrap>
<fig id="DDV007F8" position="float"><label>Figure 8.</label><caption><p>Clinically observed mutations in <italic>hETHE1</italic>. Clinically observed substitutions mapped onto the hETHE1 crystal structure. Position of hETHE1 substituted residues (sticks) mapped onto the crystal structure (PDB ID: CHL4). Structure-based sequence analysis using ConSurf reveals that substitutions occur at medium (pink) or highly conserved (magenta) residues (<xref rid="DDV007C47" ref-type="bibr">47</xref>,<xref rid="DDV007C48" ref-type="bibr">48</xref>). Tyr197 and the oxidized Cys247 are in green.</p></caption><graphic xlink:href="ddv00708"/></fig></p></sec></sec><sec sec-type="discussion" id="s3"><title>Discussion</title><p>The structural analyses clearly demonstrate that hETHE1 is an MBL-type fold as predicted by sequences analysis (<xref rid="DDV007C31" ref-type="bibr">31</xref>). The results also reveal that there are clearly specific differences in the active site metal binding of hETHE1 compared with both other eukaryotic MBL-fold enzymes (e.g. glyoxalase II) (<xref rid="DDV007C19" ref-type="bibr">19</xref>) and the classical bacterial MBLs (<xref rid="DDV007C12" ref-type="bibr">12</xref>); however, the degree of conservation is also striking. It is particularly interesting that residues involved in âclassicalâ zinc 1 and zinc 2 MBL binding are substantially (but not completely) conserved all the way through to the single-iron ion binding eukaryotic MBL-fold enzyme ETHE1 (<xref rid="DDV007C5" ref-type="bibr">5</xref>,<xref rid="DDV007C12" ref-type="bibr">12</xref>). The classical di-zinc MBLs can operate with metal ions other than zinc and use either one or two metal ions (<xref rid="DDV007C50" ref-type="bibr">50</xref>). Thus, it seems that the apparent conservation of possible âsecondâ metal-binding site residues in ETHE1 (and potentially other MBL-fold enzymes) is of functional significance. One possibility is that the activity of ETHE1 is regulated by binding of different metals, or that a di-metallic ETHE1 would have an alternative catalytic activity. It is also interesting that conserved residues in the active site of hMBLs are more similar to those present in the Class B3 bacterial MBLs compared with those of Class B1 or B2 based on sequence alignment, despite the observation that from a structural fold perspective hMBLs display higher similarity with the Class B1 and B2 bacterial MBLs in their active site architecture (Fig. <xref ref-type="fig" rid="DDV007F1">1</xref>) (<xref rid="DDV007C12" ref-type="bibr">12</xref>,<xref rid="DDV007C34" ref-type="bibr">34</xref>). It has been proposed that hMBLs evolved from an ancestor of the class B1âB2 prokaryotic MBLs based on their structural similarity (<xref rid="DDV007C35" ref-type="bibr">35</xref>,<xref rid="DDV007C51" ref-type="bibr">51</xref>), but it is also possible that eukaryotic MBL-fold proteins evolved from Class B3 bacterial MBLs, or from an ancient ancestor common to all three bacterial MBL classes.</p><p>The elucidation of the hETHE1 structure also reveals striking similarity of iron binding by enzymes of completely different overall fold, e.g. the alpha-beta-beta-alpha MBL-fold and the double-stranded beta-helix fold metal binding superfamily (<xref rid="DDV007C12" ref-type="bibr">12</xref>,<xref rid="DDV007C26" ref-type="bibr">26</xref>). Perhaps the most striking similarity is between ETHE1 and IPNS, both of which employ a facial triad of iron-binding residues and whose mechanisms both employ Fe-Sâpeptide interactions, through Fe-SCH<sub>2</sub>R in the case of IPNS (<xref rid="DDV007C25" ref-type="bibr">25</xref>) and Fe-S-SCH<sub>2</sub>R in the case of ETHE1 (<xref rid="DDV007C11" ref-type="bibr">11</xref>). Indeed the structural similarity between MBLs and IPNS was first observed on the determination of the BcII MBL structure in 1995 (<xref rid="DDV007C12" ref-type="bibr">12</xref>). The determination of the hETHE1 structure may enable the development of a detailed mechanistic understanding for ETHE1, as has been the case for crystallographic and spectroscopic studies on IPNS (<xref rid="DDV007C25" ref-type="bibr">25</xref>,<xref rid="DDV007C52" ref-type="bibr">52</xref>) and cysteine dioxygenase (<xref rid="DDV007C28" ref-type="bibr">28</xref>,<xref rid="DDV007C29" ref-type="bibr">29</xref>). The hETHE1 crystal structure will serve as a basis for detailed mechanistic studies and for insights into the basis of clinically observed substitutions causing impaired hydrogen sulfide metabolism. In this regard the observation that a cysteine residue is apparently oxidized to a sulfinic acid in hETHE1 and the ETHE1-like in <italic>A. thaliana</italic> is of interest. In the longer term it is hoped that structural insights may help to enable treatment of EE; although the development of such treatments are probably a long way off, it is notable that at least some of the clinically observed substitutions are in the putative substrate binding site, suggesting that impaired substrate binding may be an issue. Multiple metallo-enzymes are already used or are being pursued as pharmaceutical targets, with very substantial medicinal chemistry efforts being used to develop selective inhibitors (<xref rid="DDV007C16" ref-type="bibr">16</xref>,<xref rid="DDV007C53" ref-type="bibr">53</xref>,<xref rid="DDV007C54" ref-type="bibr">54</xref>). Some of these enzymes employ very similar metal coordination arrangement as observed for hETHE1. Such enzymes include MBLs themselves (<xref rid="DDV007C46" ref-type="bibr">46</xref>) in efforts to combat antibiotic resistance and, e.g. the iron and 2OG oxygenases, e.g. the hypoxia inducible-factor prolyl-hydroxylases and histone demethylases (<xref rid="DDV007C52" ref-type="bibr">52</xref>). Most of the inhibitors of these enzymes, and all of those in clinical trials, are active site binding iron chelators, which may well bind to MBL-fold iron or zinc ion utilizing enzymes (<xref rid="DDV007C55" ref-type="bibr">55</xref>,<xref rid="DDV007C56" ref-type="bibr">56</xref>). Since inhibitors of hETHE1 will likely have toxic side effects, the structural work will help to enable the development of selective metallo-enzyme inhibitors.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Protein production and purification</title><p>cDNA encoding for hETHE1 (Uniprot ID: O95571), lacking its 20 residue N-terminal mitochondrial signal sequence, was inserted into a pCOLD I vector (<italic>Addgene</italic>) to encode for hETHE1 with an N-terminal hexa-histidine tag including an N-terminal 3C human rhinovirus (HRV3C) protease cleavage site. Recombinant hETHE1 protein was produced in <italic>E. coli</italic> BL21 (DE3) cells. Cells were grown in 2TY growth media with 50 Âµg/ml ampicillin at 37Â°C to mid-exponential phase (OD 600 = 0.6â0.8). hETHE1 production was induced, by addition of 0.5 m<sc>m</sc> isopropyl Î²-<sc>d</sc>-1-thiogalactopyranoside (IPTG) and supplemented with 50 Âµ<sc>m</sc> iron sulfate while incubating at 15Â°C. Cells were harvested by centrifugation (6500 <italic>g</italic>, 8 min; centrifuge Avanti, JA-10 rotor; Beckman Coulter, Inc.), after 18 h and frozen in liquid nitrogen. About 30 g of cell pellet were added to 100 ml of lysis buffer (20 m<sc>m</sc> 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 500 m<sc>m</sc> sodium chloride and 5 m<sc>m</sc> imidazole; the pH was then adjusted to 7.5), lysed by sonication followed by centrifugation (20 000 <italic>g</italic>, 20 min; centrifuge Avanti; JLA 16.25 rotor; Beckman Coulter, Inc.). hETHE1 was purified by loading the supernatant containing hETHE1 onto a 5 ml Ni-affinity column (<ext-link ext-link-type="uri" xlink:href="http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddv007/-/DC1">Supplementary Material, Fig. S1A</ext-link>). The equilibration buffer was the same as the lysis buffer. The elution buffer additionally contained 500 m<sc>m</sc> imidazole used to form increasing imidazole concentration steps (from 5 to 500 m<sc>m</sc>) to elute His-tagged protein. hETHE1 (2 ml) was then loaded onto a S200 (300 ml) gel filtration column in 20 m<sc>m</sc> 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 500 m<sc>m</sc> sodium chloride, pH adjusted to 7.5 running buffer. Fractions containing protein were analysed by SDS-PAGE using 12% bis-acrylamide gels (<ext-link ext-link-type="uri" xlink:href="http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddv007/-/DC1">Supplementary Material, Fig. S1B</ext-link>). The 6X-His tag was cleaved by addition of HRV3C protease and incubation overnight at 4Â°C and passed over a Ni-affinity column to remove the cleaved tag from the sample (<ext-link ext-link-type="uri" xlink:href="http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddv007/-/DC1">Supplementary Material, Fig. S1C</ext-link>). Purified hETHE1 (â¼26 kDa) was buffer exchanged into 50 m<sc>m</sc> 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.5, 100 m<sc>m</sc> sodium chloride and concentrated to 10 mg/ml using a Centricon concentrator (10 k MW cutoff) centrifuged at 1200<italic>g</italic> (Centrifuge Allegra X-30, SX4400 rotor; Beckman Coulter, Inc.), until the desired volume was achieved.</p></sec><sec id="s4b"><title>Glyoxalase II activity assay</title><p>The glyoxalase activity of hETHE1 was tested using <italic>S</italic>-D-lactoylglutathione as described (<xref rid="DDV007C19" ref-type="bibr">19</xref>). The reaction was performed in a final volume of 200 Âµl, and monitored by absorbance detection using a plate reader (BMG LABTECH PHERAstar FS) in 96 well plates. The final assay mixture contained 130 Âµg of enzyme, 1 m<sc>m</sc>
<italic>S</italic>-D-lactoylglutathione and 200 Âµ<sc>m</sc> 5,5-dithiobis-(2-nitrobenzoate) (DTNB) dye (extinction coefficient at 37Â°C: 13 600 M<sup>â1</sup> cm<sup>â1</sup>) in 100 m<sc>m</sc> 3-(<italic>N</italic>-morpholino)propanesulfonic acid (MOPS), pH 7.2 buffer. Real-time glutathione formation in presence of 5-thio-2-nitrobenzoic acid was monitored at 412 nm and at 37Â°C.</p></sec><sec id="s4c"><title>Oxygen consumption assay</title><p>Persulfide substrate was prepared as previously described (<xref rid="DDV007C11" ref-type="bibr">11</xref>). Briefly, GSSH was prepared by reacting NaHS and oxidized glutathione (GSSG) under anaerobic conditions. An oxygen depleted solution of 20 m<sc>m</sc> GSSG in 100 m<sc>m</sc> sodium phosphate, pH 7.4 [100 m<sc>m</sc> sodium phosphate buffer was obtained by mixing 3.1 g of NaH<sub>2</sub>PO<sub>4</sub> and 10.9 g of Na<sub>2</sub>HPO<sub>4</sub> (anhydrous) in distilled water to give a final volume of 1 l] was mixed with an excess of NaHS. The reaction was sealed and incubated at 37Â°C for 30 min. hETHE1 activity was measured in terms of oxygen consumption during the substrate (GSSH) catalysis. A FOXY AL-300 probe and an Ocean Optics USB2000/USB2000-LS-450 spectrophotometer were used for oxygen detection. Samples were prepared as follows: 1 Âµg of hETHE1 in 25 m<sc>m</sc> HEPES, pH 7.4, 200 m<sc>m</sc> NaCl was loaded into a sealed 2 ml vial in oxygen saturated 100 m<sc>m</sc> phosphate buffer, pH 7.4. GSSH was added to a final concentration of 1 m<sc>m</sc> immediately before the measurement. The amount of oxygen is expressed as the percentage of saturation. Control samples were carried out in the absence of GSSH.</p></sec><sec id="s4d"><title>Crystallization and structure determination</title><p>hETHE1 crystallization was performed using the sitting drop vapour diffusion method in <italic>Art Robbins</italic> 96 wellsâ3 subwell Intelliplates<sup>Â®</sup> and 300 nl size drops were obtained by adding the following ratios of protein solution and reservoir buffer: 200:100,100:100, 100:200 nl to the individual subwells. The truncated hETHE1 crystallized in â¼2 weeks using the following conditions: SaltRX condition 91, 0.1 <sc>m</sc> TrisâHCl, pH 8.5, 0.5 <sc>m</sc> potassium thiocyanate (protein to reservoir ratio 2:1 and 1:1) (Hampton Research, Aliso Viejo, CA). The resulting rhombohedron-shaped crystals (â¼50 Ã 50 Âµm) were cryo-protected in well solution diluted to 25% glycerol (v/v) for 30 s, then harvested using nylon loops followed by cryo-cooling and storage in liquid nitrogen. Data were collected on a single crystal at 100 K at the Diamond Light Source synchrotron (beamline I04) to 2.6 Ã resolution. Data were autoprocessed at the beamline using XDS (<xref rid="DDV007C57" ref-type="bibr">57</xref>) and CCP4-SCALA (<xref rid="DDV007C58" ref-type="bibr">58</xref>) in XIA2 (<xref rid="DDV007C59" ref-type="bibr">59</xref>). The hETHE1 structure was solved by molecular replacement (MR) using the PHASER subroutine within PHENIX (<xref rid="DDV007C60" ref-type="bibr">60</xref>â<xref rid="DDV007C62" ref-type="bibr">62</xref>) with the <italic>A. thaliana</italic> ETHE1-like structure (PDB ID: 2GCU) (<xref rid="DDV007C31" ref-type="bibr">31</xref>) as a search model. Refinement was carried out by iterative rounds of model building using Coot (<xref rid="DDV007C63" ref-type="bibr">63</xref>) and maximum likelihood restrained refinement using PHENIX (<xref rid="DDV007C64" ref-type="bibr">64</xref>). Data collection, processing and structure refinement statistics are given in Table <xref ref-type="table" rid="DDV007TB2">2</xref>.
<table-wrap id="DDV007TB2" position="float"><label>Table 2.</label><caption><p>Crystallographic data and refinement statistics PDB ID 4CHL</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Data set</th><th align="left" rowspan="1" colspan="1">Native hETHE1</th></tr></thead><tbody><tr><td colspan="2" rowspan="1">Data collection</td></tr><tr><td rowspan="1" colspan="1">âSource</td><td rowspan="1" colspan="1">Diamond light source I04 beamline</td></tr><tr><td rowspan="1" colspan="1">âWavelength (Ã)</td><td rowspan="1" colspan="1">1.07188</td></tr><tr><td rowspan="1" colspan="1">âResolution range (Ã)</td><td rowspan="1" colspan="1">63.631â2.61 (2.68â2.61 Ã)<sup>d</sup></td></tr><tr><td rowspan="1" colspan="1">âSpace group</td><td rowspan="1" colspan="1"><italic>P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td></tr><tr><td colspan="2" rowspan="1">Unit cell parameters</td></tr><tr><td rowspan="1" colspan="1">ââ<italic>a</italic>, <italic>b</italic>, <italic>c</italic> (Ã)</td><td rowspan="1" colspan="1">73.94, 124.93, 63.09</td></tr><tr><td rowspan="1" colspan="1">ââ<italic>Î±</italic>, <italic>Î²</italic>, <italic>Î³</italic> (Â°)</td><td rowspan="1" colspan="1">90.00, 90.00, 90.00</td></tr><tr><td rowspan="1" colspan="1">âReflections (unique)</td><td rowspan="1" colspan="1">18351</td></tr><tr><td rowspan="1" colspan="1">âCompleteness (%)</td><td rowspan="1" colspan="1">99.7 (99.2)<sup>d</sup></td></tr><tr><td rowspan="1" colspan="1">âRedundancy</td><td rowspan="1" colspan="1">6.5 (6.8)<sup>d</sup></td></tr><tr><td rowspan="1" colspan="1">âR<italic>merge</italic><sup>a</sup></td><td rowspan="1" colspan="1">0.12 (0.889)<sup>d</sup></td></tr><tr><td rowspan="1" colspan="1">â&lt;<italic>I</italic>/<italic>Ï</italic> (<italic>I</italic>)&gt;</td><td rowspan="1" colspan="1">13.7 (1.9)<sup>d</sup></td></tr><tr><td colspan="2" rowspan="1">Refinement</td></tr><tr><td rowspan="1" colspan="1">âR<italic>cryst</italic><sup>b</sup>/R<italic>free</italic><sup>c</sup></td><td rowspan="1" colspan="1">0.178/0.223</td></tr><tr><td rowspan="1" colspan="1">âAnisotropy</td><td rowspan="1" colspan="1">0.754</td></tr><tr><td colspan="2" rowspan="1">RMSD</td></tr><tr><td rowspan="1" colspan="1">ââBonds (Ã)</td><td rowspan="1" colspan="1">0.01</td></tr><tr><td rowspan="1" colspan="1">ââAngles (Â°)</td><td rowspan="1" colspan="1">1.124</td></tr><tr><td rowspan="1" colspan="1">âAverage B, protein atoms (Ã<sup>2</sup>)</td><td rowspan="1" colspan="1">49.0</td></tr><tr><td colspan="2" rowspan="1">Ramachandran plot (%)</td></tr><tr><td rowspan="1" colspan="1">ââMost favoured geometry</td><td rowspan="1" colspan="1">99.1</td></tr><tr><td rowspan="1" colspan="1">ââAdditionally allowed</td><td rowspan="1" colspan="1">0.9</td></tr><tr><td rowspan="1" colspan="1">ââOutliers</td><td rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="TN2"><p><sup>a</sup>R<italic>merge</italic> = <italic>Î£<sub>h</sub></italic><italic>Î£<sub>l</sub></italic>|<italic>I<sub>hl</sub></italic> â &lt;<italic>I<sub>h</sub></italic>&gt;|/<italic>Î£<sub>h</sub></italic><italic>Î£<sub>l</sub></italic>&lt;<italic>I<sub>h</sub></italic>&gt;, where <italic>I<sub>hl</sub></italic> is the <italic>l</italic>th observation of reflection <italic>h</italic>, and &lt;<italic>I<sub>h</sub></italic>&gt; is the mean intensity of that reflection.</p></fn><fn id="TN3"><p><sup>b</sup>R<italic>cryst</italic> = <italic>Î£</italic>||<italic>F</italic><sub>obs</sub> | â |<italic>F</italic><sub>calc</sub>||/|<italic>F</italic><sub>obs</sub>|.</p></fn><fn id="TN4"><p><sup>c</sup>R<italic>free</italic> is calculated in the same way as R<italic>cryst</italic> but using a test set containing 5.13% of the data, which were excluded from the refinement calculation.</p></fn><fn id="TN5"><p><sup>d</sup>Values for highest resolution shell.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="s5"><title>Accession Number</title><p>Coordinates and structure factors have been deposited in the Protein Data Bank with accession number 4CHL.</p></sec><sec id="s6"><title>Supplementary Material</title><p><ext-link ext-link-type="uri" xlink:href="http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddv007/-/DC1">Supplementary Material is available at <italic>HMG</italic> online</ext-link>.</p></sec><sec id="s7"><title>Funding</title><p>Medical Research Council (MRC)/Canadian grant G1100135 (I.P.) and the Biotechnology and Biological Sciences Research Council (BBSRC; C.J.S). Cancer Research UK (CRUK) is acknowledged for supporting J.B. and C.J.S. Funding to pay the Open Access publication charges for this article was provided by the Oxford's RCUK Open Access Block Grant.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_24_9_2458__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_ddv007_ddv007supp.pdf"/>
</supplementary-material>
</sec>
</body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>We thank the staff at the Diamond Light Source for providing synchrotron beamtime and the Structural Genomic Consortium (SGC) for cDNA encoding for hETHE1 and Dr Opher Gileadi for discussion.</p>
      <p><italic>Conflict of Interest statement</italic>. None declared.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="DDV007C1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grosso</surname><given-names>S.</given-names></name><name><surname>Mostardini</surname><given-names>R.</given-names></name><name><surname>Farnetani</surname><given-names>M.A.</given-names></name><name><surname>Molinelli</surname><given-names>M.</given-names></name><name><surname>Berardi</surname><given-names>R.</given-names></name><name><surname>Dionisi-Vici</surname><given-names>C.</given-names></name><name><surname>Rizzo</surname><given-names>C.</given-names></name><name><surname>Morgese</surname><given-names>G.</given-names></name><name><surname>Balestri</surname><given-names>P.</given-names></name></person-group> (<year>2002</year>) <article-title>Ethylmalonic encephalopathy: further clinical and neuroradiological characterization</article-title>. <source>J. Neurol.</source>, <volume>249</volume>, <fpage>1446</fpage>â<lpage>1450</lpage>.<pub-id pub-id-type="pmid">12382164</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pigeon</surname><given-names>N.</given-names></name><name><surname>Campeau</surname><given-names>P.M.</given-names></name><name><surname>Cyr</surname><given-names>D.</given-names></name><name><surname>Lemieux</surname><given-names>B.</given-names></name><name><surname>Clarke</surname><given-names>J.T.</given-names></name></person-group> (<year>2009</year>) <article-title>Clinical heterogeneity in ethylmalonic encephalopathy</article-title>. <source>J. Child. Neurol.</source>, <volume>24</volume>, <fpage>991</fpage>â<lpage>996</lpage>.<pub-id pub-id-type="pmid">19289697</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barth</surname><given-names>M.</given-names></name><name><surname>Ottolenghi</surname><given-names>C.</given-names></name><name><surname>Hubert</surname><given-names>L.</given-names></name><name><surname>ChrÃ©tien</surname><given-names>D.</given-names></name><name><surname>Serre</surname><given-names>V.</given-names></name><name><surname>Gobin</surname><given-names>S.</given-names></name><name><surname>Romano</surname><given-names>S.</given-names></name><name><surname>Vassault</surname><given-names>A.</given-names></name><name><surname>Sefiani</surname><given-names>A.</given-names></name><name><surname>Ricquier</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2010</year>) <article-title>Multiple sources of metabolic disturbance in ETHE1-related ethylmalonic encephalopathy</article-title>. <source>J. Inherit. Metab. Dis.</source>, <volume>33</volume>, <fpage>S443</fpage>â<lpage>S453</lpage>.<pub-id pub-id-type="pmid">20978941</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiranti</surname><given-names>V.</given-names></name><name><surname>Briem</surname><given-names>E.</given-names></name><name><surname>Lamantea</surname><given-names>E.</given-names></name><name><surname>Mineri</surname><given-names>R.</given-names></name><name><surname>Papaleo</surname><given-names>E.</given-names></name><name><surname>De Gioia</surname><given-names>L.</given-names></name><name><surname>Forlani</surname><given-names>F.</given-names></name><name><surname>Rinaldo</surname><given-names>P.</given-names></name><name><surname>Dickson</surname><given-names>P.</given-names></name><name><surname>Abu-Libdeh</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2005</year>) <article-title>ETHE1 mutations are specific to ethylmalonic encephalopathy</article-title>. <source>J. Med. Genet.</source>, <volume>43</volume>, <fpage>340</fpage>â<lpage>346</lpage>.<pub-id pub-id-type="pmid">16183799</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiranti</surname><given-names>V.</given-names></name><name><surname>D'Adamo</surname><given-names>P.</given-names></name><name><surname>Briem</surname><given-names>E.</given-names></name><name><surname>Ferrari</surname><given-names>G.</given-names></name><name><surname>Mineri</surname><given-names>R.</given-names></name><name><surname>Lamantea</surname><given-names>E.</given-names></name><name><surname>Mandel</surname><given-names>H.</given-names></name><name><surname>Balestri</surname><given-names>P.</given-names></name><name><surname>Garcia-Silva</surname><given-names>M.T.</given-names></name><name><surname>Vollmer</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2004</year>) <article-title>Ethylmalonic encephalopathy is caused by mutations in <italic>ETHE1</italic>, a gene encoding a mitochondrial matrix protein</article-title>. <source>Am. J. Hum. Genet.</source>, <volume>74</volume>, <fpage>239</fpage>â<lpage>252</lpage>.<pub-id pub-id-type="pmid">14732903</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mineri</surname><given-names>R.</given-names></name><name><surname>Rimoldi</surname><given-names>M.</given-names></name><name><surname>Burlina</surname><given-names>A.B.</given-names></name><name><surname>Koskull</surname><given-names>S.</given-names></name><name><surname>Perletti</surname><given-names>C.</given-names></name><name><surname>Heese</surname><given-names>B.</given-names></name><name><surname>von Dobeln</surname><given-names>U.</given-names></name><name><surname>Mereghetti</surname><given-names>P.</given-names></name><name><surname>Di Meo</surname><given-names>I.</given-names></name><name><surname>Invernizzi</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2008</year>) <article-title>Identification of new mutations in the <italic>ETHE1</italic> gene in a cohort of 14 patients presenting with ethylmalonic encephalopathy</article-title>. <source>J. Med. Genet.</source>, <volume>45</volume>, <fpage>473</fpage>â<lpage>478</lpage>.<pub-id pub-id-type="pmid">18593870</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiranti</surname><given-names>V.</given-names></name><name><surname>Viscomi</surname><given-names>C.</given-names></name><name><surname>Hildebrandt</surname><given-names>T.</given-names></name><name><surname>Di Meo</surname><given-names>I.</given-names></name><name><surname>Mineri</surname><given-names>R.</given-names></name><name><surname>Tiveron</surname><given-names>C.</given-names></name><name><surname>Levitt</surname><given-names>M.D.</given-names></name><name><surname>Prelle</surname><given-names>A.</given-names></name><name><surname>Fagiolari</surname><given-names>G.</given-names></name><name><surname>Rimoldi</surname><given-names>M.</given-names></name><name><surname>Zeviani</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>) <article-title>Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy</article-title>. <source>Nat. Med.</source>, <volume>15</volume>, <fpage>200</fpage>â<lpage>205</lpage>.<pub-id pub-id-type="pmid">19136963</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGowan</surname><given-names>K.A.</given-names></name><name><surname>Nyhan</surname><given-names>W.L.</given-names></name><name><surname>Barshop</surname><given-names>B.A.</given-names></name><name><surname>Naviaux</surname><given-names>R.K.</given-names></name><name><surname>Yu</surname><given-names>A.</given-names></name><name><surname>Haas</surname><given-names>R.H.</given-names></name><name><surname>Townsend</surname><given-names>J.J.</given-names></name></person-group> (<year>2004</year>) <article-title>The role of methionine in ethylmalonic encephalopathy with petechiae</article-title>. <source>Arch. Neurol.</source>, <volume>61</volume>, <fpage>570</fpage>â<lpage>574</lpage>.<pub-id pub-id-type="pmid">15096407</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giordano</surname><given-names>C.</given-names></name><name><surname>Viscomi</surname><given-names>C.</given-names></name><name><surname>Orlandi</surname><given-names>M.</given-names></name><name><surname>Papoff</surname><given-names>P.</given-names></name><name><surname>Spalice</surname><given-names>A.</given-names></name><name><surname>Burlina</surname><given-names>A.</given-names></name><name><surname>Di Meo</surname><given-names>I.</given-names></name><name><surname>Tiranti</surname><given-names>V.</given-names></name><name><surname>Leuzzi</surname><given-names>V.</given-names></name><name><surname>d'Amati</surname><given-names>G.</given-names></name><name><surname>Zeviani</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>) <article-title>Morphologic evidence of diffuse vascular damage in human and in the experimental model of ethylmalonic encephalopathy</article-title>. <source>J. Inherit. Metab. Dis.</source>, <volume>35</volume>, <fpage>451</fpage>â<lpage>458</lpage>.<pub-id pub-id-type="pmid">22020834</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coletta</surname><given-names>C.</given-names></name></person-group> (<year>2012</year>) <article-title>Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>, <volume>109</volume>, <fpage>9161</fpage>â<lpage>9166</lpage>.<pub-id pub-id-type="pmid">22570497</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabil</surname><given-names>O.</given-names></name><name><surname>Banerjee</surname><given-names>R.</given-names></name></person-group> (<year>2012</year>) <article-title>Characterization of patient mutations in human persulfide dioxygenase (ETHE1) involved in H<sub>2</sub>S catabolism</article-title>. <source>J. Biol. Chem.</source>, <volume>287</volume>, <fpage>44561</fpage>â<lpage>44567</lpage>.<pub-id pub-id-type="pmid">23144459</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carfi</surname><given-names>A.</given-names></name><name><surname>Pares</surname><given-names>S.</given-names></name><name><surname>DuÃ©e</surname><given-names>E.</given-names></name><name><surname>Galleni</surname><given-names>M.</given-names></name><name><surname>Duez</surname><given-names>C.</given-names></name><name><surname>FrÃ¨re</surname><given-names>J.M.</given-names></name><name><surname>Dideberg</surname><given-names>O.</given-names></name></person-group> (<year>1995</year>) <article-title>The 3-D structure of a zinc metallo-beta-lactamase from <italic>Bacillus cereus</italic> reveals a new type of protein fold</article-title>. <source>EMBO J.</source>, <volume>14</volume>, <fpage>4914</fpage>â<lpage>4921</lpage>.<pub-id pub-id-type="pmid">7588620</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bush</surname><given-names>K.</given-names></name></person-group> (<year>2013</year>) <article-title>Proliferation and significance of clinically relevant beta-lactamases</article-title>. <source>Ann. N. Y. Acad. Sci.</source>, <volume>1277</volume>, <fpage>84</fpage>â<lpage>90</lpage>.<pub-id pub-id-type="pmid">23346859</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornaglia</surname><given-names>G.</given-names></name><name><surname>Akova</surname><given-names>M.</given-names></name><name><surname>Amicosante</surname><given-names>G.</given-names></name><name><surname>CantÃ³n</surname><given-names>R.</given-names></name><name><surname>Cauda</surname><given-names>R.</given-names></name><name><surname>Docquier</surname><given-names>J.D.</given-names></name><name><surname>Edelstein</surname><given-names>M.</given-names></name><name><surname>FrÃ¨re</surname><given-names>J.M.</given-names></name><name><surname>Fuzi</surname><given-names>M.</given-names></name><name><surname>Galleni</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2007</year>) <article-title>Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues</article-title>. <source>Int. J. Antimicrob. Agents</source>, <volume>29</volume>, <fpage>380</fpage>â<lpage>388</lpage>.<pub-id pub-id-type="pmid">17223319</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LiÃ©nard</surname><given-names>B.M.</given-names></name><name><surname>Garau</surname><given-names>G.</given-names></name><name><surname>Horsfall</surname><given-names>L.</given-names></name><name><surname>Karsisiotis</surname><given-names>A.I.</given-names></name><name><surname>Damblon</surname><given-names>C.</given-names></name><name><surname>Lassaux</surname><given-names>P.</given-names></name><name><surname>Papamicael</surname><given-names>C.</given-names></name><name><surname>Roberts</surname><given-names>G.C.</given-names></name><name><surname>Galleni</surname><given-names>M.</given-names></name><name><surname>Dideberg</surname><given-names>O.</given-names></name><name><surname>FrÃ¨re</surname><given-names>J.M.</given-names></name><name><surname>Schofield</surname><given-names>C.J.</given-names></name></person-group> (<year>2008</year>) <article-title>Structural basis for the broad-spectrum inhibition of metallo-beta-lactamases by thiols</article-title>. <source>Org. Biomol. Chem.</source>, <volume>6</volume>, <fpage>2282</fpage>â<lpage>2294</lpage>.<pub-id pub-id-type="pmid">18563261</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lombardi</surname><given-names>P.M.</given-names></name><name><surname>Cole</surname><given-names>K.E.</given-names></name><name><surname>Dowling</surname><given-names>D.P.</given-names></name><name><surname>Christianson</surname><given-names>D.W.</given-names></name></person-group> (<year>2011</year>) <article-title>Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes</article-title>. <source>Curr. Opin. Struct. Biol.</source>, <volume>21</volume>, <fpage>735</fpage>â<lpage>743</lpage>.<pub-id pub-id-type="pmid">21872466</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galleni</surname><given-names>M.</given-names></name><name><surname>Lamotte-Brasseur</surname><given-names>J.</given-names></name><name><surname>Rossolini</surname><given-names>G.M.</given-names></name><name><surname>Spencer</surname><given-names>J.</given-names></name><name><surname>Dideberg</surname><given-names>O.</given-names></name><name><surname>FrÃ¨re</surname><given-names>J.M.</given-names></name></person-group>; <collab>Metallo-beta-lactamases Working Group</collab>. (<year>2001</year>) <article-title>Standard numbering scheme for class B beta-lactamases</article-title>. <source>Antimicrob. Agents Chemother.</source>, <volume>45</volume>, <fpage>660</fpage>â<lpage>663</lpage>.<pub-id pub-id-type="pmid">11181339</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baier</surname><given-names>F.</given-names></name><name><surname>Tokuriki</surname><given-names>N.</given-names></name></person-group> (<year>2014</year>) <article-title>Connectivity between catalytic landscapes of the metallo-Î²-lactamase superfamily</article-title>. <source>J. Mol. Biol.</source>, <volume>426</volume>, <fpage>2442</fpage>â<lpage>2456</lpage>.<pub-id pub-id-type="pmid">24769192</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>RidderstrÃ¶m</surname><given-names>M.</given-names></name><name><surname>Saccucci</surname><given-names>F.</given-names></name><name><surname>Hellman</surname><given-names>U.</given-names></name><name><surname>Bergman</surname><given-names>T.</given-names></name><name><surname>Principato</surname><given-names>G.</given-names></name><name><surname>Mannervik</surname><given-names>B.</given-names></name></person-group> (<year>1996</year>) <article-title>Molecular cloning, heterologous expression, and characterization of human glyoxalase II</article-title>. <source>J. Biol. Chem.</source>, <volume>271</volume>, <fpage>319</fpage>â<lpage>323</lpage>.<pub-id pub-id-type="pmid">8550579</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cattell</surname><given-names>E.</given-names></name><name><surname>SengerovÃ¡</surname><given-names>B.</given-names></name><name><surname>McHugh</surname><given-names>P.J.</given-names></name></person-group> (<year>2010</year>) <article-title>The SNM1/Pso2 family of ICL repair nucleases: from yeast to man</article-title>. <source>Environ. Mol. Mutagen.</source>, <volume>51</volume>, <fpage>635</fpage>â<lpage>645</lpage>.<pub-id pub-id-type="pmid">20175117</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandel</surname><given-names>C.R.</given-names></name><name><surname>Kaneko</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Gebauer</surname><given-names>D.</given-names></name><name><surname>Vethantham</surname><given-names>V.</given-names></name><name><surname>Manley</surname><given-names>J.L.</given-names></name><name><surname>Tong</surname><given-names>L.</given-names></name></person-group> (<year>2006</year>) <article-title>Polyadenylation factor CPSF-73 is the pre-mRNA 3â²-end-processing endonuclease</article-title>. <source>Nature</source>, <volume>444</volume>, <fpage>953</fpage>â<lpage>956</lpage>.<pub-id pub-id-type="pmid">17128255</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiffer</surname><given-names>S.</given-names></name><name><surname>Rosch</surname><given-names>S.</given-names></name><name><surname>Marchfelder</surname><given-names>A.</given-names></name></person-group> (<year>2002</year>) <article-title>Assigning a function to a conserved group of proteins: the tRNA 3â²-processing enzymes</article-title>. <source>EMBO J.</source>, <volume>21</volume>, <fpage>2769</fpage>â<lpage>2777</lpage>.<pub-id pub-id-type="pmid">12032089</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daiyasu</surname><given-names>H.</given-names></name><name><surname>Osaka</surname><given-names>K.</given-names></name><name><surname>Ishino</surname><given-names>Y.</given-names></name><name><surname>Toh</surname><given-names>H.</given-names></name></person-group> (<year>2001</year>) <article-title>Expansion of the zinc metallo-hydrolase family of the beta-lactamase fold</article-title>. <source>FEBS Lett.</source>, <volume>503</volume>, <fpage>1</fpage>â<lpage>6</lpage>.<pub-id pub-id-type="pmid">11513844</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schilling</surname><given-names>O.</given-names></name><name><surname>Wenzel</surname><given-names>N.</given-names></name><name><surname>Naylor</surname><given-names>M.</given-names></name><name><surname>Vogel</surname><given-names>A.</given-names></name><name><surname>Crowder</surname><given-names>M.</given-names></name><name><surname>Makaroff</surname><given-names>C.</given-names></name><name><surname>Meyer-Klaucke</surname><given-names>W.</given-names></name></person-group> (<year>2003</year>) <article-title>Flexible metal binding of the metallo-beta-lactamase domain: glyoxalase II incorporates iron, manganese, and zinc in vivo</article-title>. <source>Biochemistry</source>, <volume>42</volume>, <fpage>11777</fpage>â<lpage>11786</lpage>.<pub-id pub-id-type="pmid">14529289</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roach</surname><given-names>P.L.</given-names></name><name><surname>Clifton</surname><given-names>I.J.</given-names></name><name><surname>Hensgens</surname><given-names>C.M.</given-names></name><name><surname>Shibata</surname><given-names>N.</given-names></name><name><surname>Schofield</surname><given-names>C.J.</given-names></name><name><surname>Hajdu</surname><given-names>J.</given-names></name><name><surname>Baldwin</surname><given-names>J.E.</given-names></name></person-group> (<year>1997</year>) <article-title>Structure of isopenicillin <italic>N</italic> synthase complexed with substrate and the mechanism of penicillin formation</article-title>. <source>Nature</source>, <volume>387</volume>, <fpage>827</fpage>â<lpage>830</lpage>.<pub-id pub-id-type="pmid">9194566</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C26">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roach</surname><given-names>P.L.</given-names></name><name><surname>Clifton</surname><given-names>I.J.</given-names></name><name><surname>FÃ¼lÃ¶p</surname><given-names>V.</given-names></name><name><surname>Harlos</surname><given-names>K.</given-names></name><name><surname>Barton</surname><given-names>G.J.</given-names></name><name><surname>Hajdu</surname><given-names>J.</given-names></name><name><surname>Andersson</surname><given-names>I.</given-names></name><name><surname>Schofield</surname><given-names>C.J.</given-names></name><name><surname>Baldwin</surname><given-names>J.</given-names></name></person-group> (<year>1995</year>) <article-title>Crystal structure of isopenicillin <italic>N</italic> synthase is the first from a new structural family of enzymes</article-title>. <source>Nature</source>, <volume>375</volume>, <fpage>700</fpage>â<lpage>704</lpage>.<pub-id pub-id-type="pmid">7791906</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamed</surname><given-names>R.B.</given-names></name><name><surname>Gomez-Castellanos</surname><given-names>J.R.</given-names></name><name><surname>Henry</surname><given-names>L.</given-names></name><name><surname>Ducho</surname><given-names>C.</given-names></name><name><surname>McDonough</surname><given-names>M.A.</given-names></name><name><surname>Schofield</surname><given-names>C.J.</given-names></name></person-group> (<year>2013</year>) <article-title>The enzymes of Î²-lactam biosynthesis</article-title>. <source>Nat. Prod. Rep.</source>, <volume>30</volume>, <fpage>21</fpage>â<lpage>107</lpage>.<pub-id pub-id-type="pmid">23135477</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaesi</surname><given-names>E.J.</given-names></name><name><surname>Fox</surname><given-names>B.G.</given-names></name><name><surname>Brunold</surname><given-names>T.C.</given-names></name></person-group> (<year>2014</year>) <article-title>Spectroscopic and computational investigation of iron (III) cysteine dioxygenase: implications for the nature of the putative superoxo-Fe(III) intermediate</article-title>. <source>Biochemistry</source>, <volume>53</volume>, <fpage>5759</fpage>â<lpage>5770</lpage>.<pub-id pub-id-type="pmid">25093959</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souness</surname><given-names>R.J.</given-names></name><name><surname>Kleffmann</surname><given-names>T.</given-names></name><name><surname>Tchesnokov</surname><given-names>E.P.</given-names></name><name><surname>Wilbanks</surname><given-names>S.M.</given-names></name><name><surname>Jameson</surname><given-names>G.B.</given-names></name><name><surname>Jameson</surname><given-names>G.N.</given-names></name></person-group> (<year>2013</year>) <article-title>Mechanistic implications of persulfenate and persulfide binding in the active site of cysteine dioxygenase</article-title>. <source>Biochemistry</source>, <volume>52</volume>, <fpage>7606</fpage>â<lpage>7617</lpage>.<pub-id pub-id-type="pmid">24084026</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C30">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown-Marshall</surname><given-names>C.D.</given-names></name><name><surname>Diebold</surname><given-names>A.R.</given-names></name><name><surname>Solomon</surname><given-names>E.I.</given-names></name></person-group> (<year>2010</year>) <article-title>Reaction coordinate of isopenicillin <italic>N</italic> synthase: oxidase versus oxygenase activity</article-title>. <source>Biochemistry</source>, <volume>49</volume>, <fpage>1176</fpage>â<lpage>1182</lpage>.<pub-id pub-id-type="pmid">20078029</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C31">
        <label>31</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname><given-names>J.G.</given-names></name><name><surname>Bingman</surname><given-names>C.A.</given-names></name><name><surname>Bitto</surname><given-names>E.</given-names></name><name><surname>Holdorf</surname><given-names>M.M.</given-names></name><name><surname>Makaroff</surname><given-names>C.A.</given-names></name><name><surname>Phillips</surname><given-names>G.N.</given-names><suffix>Jr</suffix></name></person-group> (<year>2006</year>) <article-title>Structure of an ETHE1-like protein from <italic>Arabidopsis thaliana</italic></article-title>. <source>Acta Crystallogr. D Biol. Crystallogr.</source>, <volume>62</volume>, <fpage>964</fpage>â<lpage>970</lpage>.<pub-id pub-id-type="pmid">16929096</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C32">
        <label>32</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Berkel</surname><given-names>S.S.</given-names></name><name><surname>Brem</surname><given-names>J.</given-names></name><name><surname>Rydzik</surname><given-names>A.M.</given-names></name><name><surname>Salimraj</surname><given-names>R.</given-names></name><name><surname>Cain</surname><given-names>R.</given-names></name><name><surname>Verma</surname><given-names>A.</given-names></name><name><surname>Owens</surname><given-names>R.J.</given-names></name><name><surname>Fishwick</surname><given-names>C.W.</given-names></name><name><surname>Spencer</surname><given-names>J.</given-names></name><name><surname>Schofield</surname><given-names>C.J.</given-names></name></person-group> (<year>2013</year>) <article-title>Assay platform for clinically relevant metallo-Î²-lactamases</article-title>. <source>J. Med. Chem.</source>, <volume>56</volume>, <fpage>6945</fpage>â<lpage>6953</lpage>.<pub-id pub-id-type="pmid">23898798</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C33">
        <label>33</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holdorf</surname><given-names>M.M.</given-names></name><name><surname>Bennett</surname><given-names>B.</given-names></name><name><surname>Crowder</surname><given-names>M.W.</given-names></name><name><surname>Makaroff</surname><given-names>C.A.</given-names></name></person-group> (<year>2008</year>) <article-title>Spectroscopic studies on <italic>Arabidopsis</italic> ETHE1, a glyoxalase II-like protein</article-title>. <source>J. Inorg. Biochem.</source>, <volume>102</volume>, <fpage>1825</fpage>â<lpage>1830</lpage>.<pub-id pub-id-type="pmid">18656261</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C34">
        <label>34</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krissinel</surname><given-names>E.</given-names></name><name><surname>Henrick</surname><given-names>K.</given-names></name></person-group> (<year>2007</year>) <article-title>Protein interfaces, surfaces and assemblies service PISA at the European Bioinformatics Institute. Inference of macromolecular assemblies from crystalline state</article-title>. (<comment><uri xlink:type="simple" xlink:href="http://www.ebi.ac.uk/pdbe/prot_int/pistart.html">http://www.ebi.ac.uk/pdbe/prot_int/pistart.html</uri></comment>). <source>J. Mol. Biol.</source>, <volume>372</volume>, <fpage>774</fpage>â<lpage>797</lpage>.<pub-id pub-id-type="pmid">17681537</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C35">
        <label>35</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bebrone</surname><given-names>C.</given-names></name></person-group> (<year>2007</year>) <article-title>Metallo-beta-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily</article-title>. <source>Biochem. Pharmacol.</source>, <volume>74</volume>, <fpage>1686</fpage>â<lpage>1701</lpage>.<pub-id pub-id-type="pmid">17597585</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C36">
        <label>36</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadopoulos</surname><given-names>J.S.</given-names></name><name><surname>Agarwala</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>) <article-title>COBALT: constraint-based alignment tool for multiple protein sequences</article-title>. <source>Bioinformatics</source>, <volume>23</volume>, <fpage>1073</fpage>â<lpage>1079</lpage>.<pub-id pub-id-type="pmid">17332019</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C37">
        <label>37</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altschul</surname><given-names>S.F.</given-names></name><name><surname>Madden</surname><given-names>T.L.</given-names></name><name><surname>SchÃ¤ffer</surname><given-names>A.A.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Miller</surname><given-names>W.</given-names></name><name><surname>Lipman</surname><given-names>D.J.</given-names></name></person-group> (<year>1997</year>) <article-title>Gapped BLAST and PSI-BLAST: a new generation of protein database search programs</article-title>. <source>Nucleic Acids Res.</source>, <volume>25</volume>, <fpage>3389</fpage>â<lpage>3402</lpage>.<pub-id pub-id-type="pmid">9254694</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C38">
        <label>38</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>X.</given-names></name><name><surname>Gouet</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>) <article-title>Deciphering key features in protein structures with the new ENDscript server</article-title>. <source>Nucleic Acids Res.</source>, <volume>42</volume>, <fpage>320</fpage>â<lpage>324</lpage>.</mixed-citation>
      </ref>
      <ref id="DDV007C39">
        <label>39</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsujimura</surname><given-names>M.</given-names></name><name><surname>Dohmae</surname><given-names>N.</given-names></name><name><surname>Odaka</surname><given-names>M.</given-names></name><name><surname>Chijimatsu</surname><given-names>M.</given-names></name><name><surname>Takio</surname><given-names>K.</given-names></name><name><surname>Yohda</surname><given-names>M.</given-names></name><name><surname>Hoshino</surname><given-names>M.</given-names></name><name><surname>Nagashima</surname><given-names>S.</given-names></name><name><surname>Endo</surname><given-names>I.</given-names></name></person-group> (<year>1997</year>) <article-title>Structure of the photoreactive iron center of the nitrile hydratase from <italic>Rhodococcus</italic> sp. N-771. Evidence of a novel post-translational modification in the cysteine ligand</article-title>. <source>J. Biol. Chem.</source>, <volume>272</volume>, <fpage>29454</fpage>â<lpage>29459</lpage>.<pub-id pub-id-type="pmid">9368004</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C40">
        <label>40</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>Y.</given-names></name><name><surname>Sasaki</surname><given-names>S.</given-names></name><name><surname>Herai</surname><given-names>S.</given-names></name><name><surname>Oinuma</surname><given-names>K.</given-names></name><name><surname>Shimizu</surname><given-names>S.</given-names></name><name><surname>Kobayashi</surname><given-names>M.</given-names></name></person-group> (<year>2002</year>) <article-title>Site-directed mutagenesis for cysteine residues of cobalt-containing nitrile hydratase</article-title>. <source>J. Inorg. Biochem.</source>, <volume>91</volume>, <fpage>70</fpage>â<lpage>77</lpage>.<pub-id pub-id-type="pmid">12121763</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C41">
        <label>41</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantri</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>McDonough</surname><given-names>M.A.</given-names></name><name><surname>Schofield</surname><given-names>C.J.</given-names></name></person-group> (<year>2012</year>) <article-title>Autocatalysed oxidative modifications to 2-oxoglutarate dependent oxygenases</article-title>. <source>FEBS J.</source>, <volume>279</volume>, <fpage>1563</fpage>â<lpage>1575</lpage>.<pub-id pub-id-type="pmid">22251775</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C42">
        <label>42</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rees</surname><given-names>D.C.</given-names></name><name><surname>Rochette</surname><given-names>J.</given-names></name><name><surname>Schofield</surname><given-names>C.</given-names></name><name><surname>Green</surname><given-names>B.</given-names></name><name><surname>Morris</surname><given-names>M.</given-names></name><name><surname>Parker</surname><given-names>N.E.</given-names></name><name><surname>Sasaki</surname><given-names>H.</given-names></name><name><surname>Tanaka</surname><given-names>A.</given-names></name><name><surname>Ohba</surname><given-names>Y.</given-names></name><name><surname>Clegg</surname><given-names>J.B.</given-names></name></person-group> (<year>1996</year>) <article-title>A novel silent posttranslational mechanism converts methionine to aspartate in hemoglobin Bristol (beta 67[E11] Val-Met-&gt;Asp)</article-title>. <source>Blood</source>, <volume>88</volume>, <fpage>341</fpage>â<lpage>348</lpage>.<pub-id pub-id-type="pmid">8704193</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C43">
        <label>43</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T.B.</given-names></name><name><surname>Liu</surname><given-names>X.H.</given-names></name><name><surname>Feng</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>W.X.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.G.</given-names></name><name><surname>Gong</surname><given-names>L.M.</given-names></name></person-group> (<year>2004</year>) <article-title>Characterization of MR-1, a novel myofibrillogenesis regulator in human muscle</article-title>. <source>Acta. Biochim. Biophys. Sin.</source>, <volume>36</volume>, <fpage>412</fpage>â<lpage>418</lpage>.<pub-id pub-id-type="pmid">15188056</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C44">
        <label>44</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>W.C.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Butch</surname><given-names>S.E.</given-names></name><name><surname>Rosenzweig</surname><given-names>A.C.</given-names></name><name><surname>Boal</surname><given-names>A.K.</given-names></name><name><surname>Krebs</surname><given-names>C.</given-names></name><name><surname>Bollinger</surname><given-names>J.M.</given-names><suffix>Jr</suffix></name></person-group> (<year>2014</year>) <article-title>Mechanism of the C5 stereoinversion reaction in the biosynthesis of carbapenem antibiotics</article-title>. <source>Science</source>, <volume>343</volume>, <fpage>1140</fpage>â<lpage>1144</lpage>.<pub-id pub-id-type="pmid">24604200</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C45">
        <label>45</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clifton</surname><given-names>I.J.</given-names></name><name><surname>Doan</surname><given-names>L.X.</given-names></name><name><surname>Sleeman</surname><given-names>M.C.</given-names></name><name><surname>Topf</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name><name><surname>Wilmouth</surname><given-names>R.C.</given-names></name><name><surname>Schofield</surname><given-names>C.J.</given-names></name></person-group> (<year>2003</year>) <article-title>Crystal structure of carbapenem synthase (CarC)</article-title>. <source>J. Biol. Chem.</source>, <volume>278</volume>, <fpage>20843</fpage>â<lpage>20850</lpage>.<pub-id pub-id-type="pmid">12611886</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C46">
        <label>46</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faridoon</surname></name><name><surname>Ul Islam</surname><given-names>N.</given-names></name></person-group> (<year>2013</year>) <article-title>An update on the status of potent inhibitors of metallo-Î²-lactamases</article-title>. <source>Sci. Pharm.</source>, <volume>81</volume>, <fpage>309</fpage>â<lpage>327</lpage>.<pub-id pub-id-type="pmid">23833706</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C47">
        <label>47</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glaser</surname><given-names>F.</given-names></name><name><surname>Pupko</surname><given-names>T.</given-names></name><name><surname>Paz</surname><given-names>I.</given-names></name><name><surname>Bell</surname><given-names>R.E.</given-names></name><name><surname>Bechor</surname><given-names>D.</given-names></name><name><surname>Martz</surname><given-names>E.</given-names></name><name><surname>Ben-Tal</surname><given-names>N.</given-names></name></person-group> (<year>2003</year>) <article-title>ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information</article-title>. <source>Bioinformatics</source>, <volume>19</volume>, <fpage>163</fpage>â<lpage>164</lpage>.<pub-id pub-id-type="pmid">12499312</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C48">
        <label>48</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landau</surname><given-names>M.</given-names></name><name><surname>Mayrose</surname><given-names>I.</given-names></name><name><surname>Rosenberg</surname><given-names>Y.</given-names></name><name><surname>Glaser</surname><given-names>F.</given-names></name><name><surname>Martz</surname><given-names>E.</given-names></name><name><surname>Pupko</surname><given-names>T.</given-names></name><name><surname>Ben-Tal</surname><given-names>N.</given-names></name></person-group> (<year>2005</year>) <article-title>ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures</article-title><italic>.</italic>
<source>Nucleic Acids Res.</source>, <volume>33</volume>, <fpage>299</fpage>â<lpage>302</lpage>.</mixed-citation>
      </ref>
      <ref id="DDV007C49">
        <label>49</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henriques</surname><given-names>B.J.</given-names></name><name><surname>Lucas</surname><given-names>T.G.</given-names></name><name><surname>Rodrigues</surname><given-names>J.V.</given-names></name><name><surname>Frederiksen</surname><given-names>J.H.</given-names></name><name><surname>Teixeira</surname><given-names>M.S.</given-names></name><name><surname>Tiranti</surname><given-names>V.</given-names></name><name><surname>Bross</surname><given-names>P.</given-names></name><name><surname>Gomes</surname><given-names>C.M.</given-names></name></person-group> (<year>2014</year>) <article-title>Ethylmalonic encephalopathy ETHE1 R163W/R163Q mutations alter protein stability and redox properties of the iron centre</article-title>. <source>PLoS One</source>, <volume>9</volume>, <fpage>e107157</fpage>.<pub-id pub-id-type="pmid">25198162</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C50">
        <label>50</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karsisiotis</surname><given-names>A.I.</given-names></name><name><surname>Damblon</surname><given-names>C.F.</given-names></name><name><surname>Roberts</surname><given-names>G.C.</given-names></name></person-group> (<year>2014</year>) <article-title>A variety of roles for versatile zinc in metallo-Î²-lactamases</article-title>. <source>Metallomics</source>, <volume>6</volume>, <fpage>1181</fpage>â<lpage>1197</lpage>.<pub-id pub-id-type="pmid">24696003</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C51">
        <label>51</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garau</surname><given-names>G.</given-names></name><name><surname>Di Guilmi</surname><given-names>A.M.</given-names></name><name><surname>Hall</surname><given-names>B.G.</given-names></name></person-group> (<year>2005</year>) <article-title>Structure-based phylogeny of the metallo-beta-lactamases</article-title>. <source>Antimicrob. Agents Chemother.</source>, <volume>49</volume>, <fpage>2778</fpage>â<lpage>2784</lpage>.<pub-id pub-id-type="pmid">15980349</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C52">
        <label>52</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>V.J.</given-names></name><name><surname>Orville</surname><given-names>A.M.</given-names></name><name><surname>Harpel</surname><given-names>M.R.</given-names></name><name><surname>Frolik</surname><given-names>C.A.</given-names></name><name><surname>Surerus</surname><given-names>K.K.</given-names></name><name><surname>MÃ¼nck</surname><given-names>E.</given-names></name><name><surname>Lipscomb</surname><given-names>J.D.</given-names></name></person-group> (<year>1989</year>) <article-title>Spectroscopic studies of isopenicillin <italic>N</italic> synthase. A mononuclear nonheme Fe<sup>2+</sup> oxidase with metal coordination sites for small molecules and substrate</article-title>. <source>J. Biol. Chem.</source>, <volume>264</volume>, <fpage>21677</fpage>â<lpage>21681</lpage>.<pub-id pub-id-type="pmid">2557336</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C53">
        <label>53</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>N.R.</given-names></name><name><surname>McDonough</surname><given-names>M.A.</given-names></name><name><surname>King</surname><given-names>O.N.</given-names></name><name><surname>Kawamura</surname><given-names>A.</given-names></name><name><surname>Schofield</surname><given-names>C.J.</given-names></name></person-group> (<year>2011</year>) <article-title>Inhibition of 2-oxoglutarate dependent oxygenases</article-title>. <source>Chem. Soc. Rev.</source>, <volume>40</volume>, <fpage>4364</fpage>â<lpage>4397</lpage>.<pub-id pub-id-type="pmid">21390379</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C54">
        <label>54</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drawz</surname><given-names>S.M.</given-names></name><name><surname>Papp-Wallace</surname><given-names>K.M.</given-names></name><name><surname>Bonomo</surname><given-names>R.A.</given-names></name></person-group> (<year>2014</year>) <article-title>New Î²-lactamase inhibitors: a therapeutic renaissance in an MDR world</article-title>. <source>Antimicrob. Agents Chemother.</source>, <volume>58</volume>, <fpage>1835</fpage>â<lpage>1846</lpage>.<pub-id pub-id-type="pmid">24379206</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C55">
        <label>55</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buynak</surname><given-names>J.D.</given-names></name></person-group> (<year>2013</year>) <article-title>Î²-Lactamase inhibitors: a review of the patent literature (2010â2013)</article-title>. <source>Expert. Opin. Ther. Pat.</source>, <volume>23</volume>, <fpage>1469</fpage>â<lpage>1481</lpage>.<pub-id pub-id-type="pmid">23967802</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C56">
        <label>56</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fast</surname><given-names>W.</given-names></name><name><surname>Sutton</surname><given-names>L.D.</given-names></name></person-group> (<year>2013</year>) <article-title>Metallo-Î²-lactamase: inhibitors and reporter substrates</article-title>. <source>Biochim. Biophys. Acta</source>, <volume>1834</volume>, <fpage>1648</fpage>â<lpage>1659</lpage>.<pub-id pub-id-type="pmid">23632317</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C57">
        <label>57</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabsch</surname><given-names>W.</given-names></name></person-group> (<year>2010</year>) <article-title>XDS</article-title>. <source>Acta Crystallogr. D Biol. Crystallogr.</source>, <volume>D66</volume>, <fpage>125</fpage>â<lpage>132</lpage>.<pub-id pub-id-type="pmid">20124692</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C58">
        <label>58</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>P.</given-names></name></person-group> (<year>2006</year>) <article-title>Scaling and assessment of data quality</article-title>. <source>Acta Crystallogr. D Biol. Crystallogr.</source>, <volume>D62</volume>, <fpage>72</fpage>â<lpage>82</lpage>.<pub-id pub-id-type="pmid">16369096</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C59">
        <label>59</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>G.</given-names></name></person-group> (<year>2010</year><italic>)</italic>
<article-title><italic>xia2</italic>: an expert system for macromolecular crystallography data reduction</article-title>. <source>J. Appl. Cryst.</source>, <volume>43</volume>, <fpage>186</fpage>â<lpage>190</lpage>.</mixed-citation>
      </ref>
      <ref id="DDV007C60">
        <label>60</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Read</surname><given-names>R.J.</given-names></name></person-group> (<year>2001</year>) <article-title>Pushing the boundaries of molecular replacement with maximum likelihood</article-title>. <source>Acta Crystallogr. D Biol. Crystallogr.</source>, <volume>57</volume>, <fpage>1373</fpage>â<lpage>1382</lpage>.<pub-id pub-id-type="pmid">11567148</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C61">
        <label>61</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>P.D.</given-names></name><name><surname>Gopal</surname><given-names>K.</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>R.W.</given-names></name><name><surname>Hung</surname><given-names>L-W.</given-names></name><name><surname>Ioerger</surname><given-names>T.R.</given-names></name><name><surname>McCoy</surname><given-names>A.J.</given-names></name><name><surname>Moriarty</surname><given-names>N.W.</given-names></name><name><surname>Pai</surname><given-names>R.K.</given-names></name><name><surname>Read</surname><given-names>R.J.</given-names></name><name><surname>Romo</surname><given-names>T.D.</given-names></name><etal/></person-group> (<year>2004</year>) <article-title>Recent developments in the PHENIX software for automated crystallographic structure determination</article-title>. <source>J. Synchrotron Radiat.</source>, <volume>11</volume>, <fpage>53</fpage>â<lpage>55</lpage>.<pub-id pub-id-type="pmid">14646133</pub-id></mixed-citation>
      </ref>
      <ref id="DDV007C62">
        <label>62</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>P.D.</given-names></name><name><surname>Afonine</surname><given-names>P.V.</given-names></name><name><surname>BunkÃ³czi</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>V.B.</given-names></name><name><surname>Davis</surname><given-names>I.W.</given-names></name><name><surname>Echols</surname><given-names>N.</given-names></name><name><surname>Headd</surname><given-names>J.J.</given-names></name><name><surname>Hung</surname><given-names>L-W.</given-names></name><name><surname>Kapral</surname><given-names>G.J.</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>R.W.</given-names></name><etal/></person-group> (<year>2010</year>) <article-title>PHENIX: a comprehensive Python-based system for macromolecular structure solution</article-title>. <source>Acta Cryst.</source>, <volume>D66</volume>, <fpage>213</fpage>â<lpage>221</lpage>.</mixed-citation>
      </ref>
      <ref id="DDV007C63">
        <label>63</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P.</given-names></name><name><surname>Lohkamp</surname><given-names>B.</given-names></name><name><surname>Scott</surname><given-names>W.G.</given-names></name><name><surname>Cowtan</surname><given-names>K.</given-names></name></person-group> (<year>2010</year>) <article-title>Features and development of coot</article-title>. <source>Acta Cryst.</source>, <volume>D66</volume>, <fpage>486</fpage>â<lpage>501</lpage>.</mixed-citation>
      </ref>
      <ref id="DDV007C64">
        <label>64</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afonine</surname><given-names>P.V.</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>R.W.</given-names></name><name><surname>Adams</surname><given-names>P.D.</given-names></name></person-group> (<year>2005</year>) <article-title>Robust bulk-solvent correction and anisotropic scaling procedure</article-title>. <source>Acta Crystallogr. D Biol. Crystallogr.</source>, <volume>D61</volume>, <fpage>850</fpage>â<lpage>855</lpage>.<pub-id pub-id-type="pmid">15983406</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>